Positive
From GlobeNewswire: 2025-03-06 13:00:00
- TCR therapy is gaining momentum in cancer treatment, with 80+ pharma companies developing over 100 pipeline therapies. Key companies like Immunocore and Neogene Therapeutics are advancing Brenetafusp and TAEST 16001 for melanoma and soft tissue sarcoma.
- Immatics N.V. and Affini-T Therapeutics presented promising clinical data for their TCR therapies in ongoing trials, showing potential for improved cancer treatment outcomes.
- Matica Biotechnology and Cellipont Bioservices are collaborating with Mongoose Bio to advance lentivirus-based TCR-T cell therapies for cancer treatment.
- Learn more about the TCR therapy pipeline insights and clinical trials to understand the future of cancer treatment and the potential of TCR-engineered T cells.
- DelveInsight offers comprehensive reports on TCR therapy, melanoma pipeline, and oncology conference coverage, providing valuable insights for pharmaceutical companies to enhance their performance in the life sciences sector.
Read more at GlobeNewswire: TCR Therapy Clinical Trial Pipeline Accelerates as 80+